NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
Clinical Trials
11 trialsNCT00625846 2020-02-26
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02393820 2019-10-29
PACSA-ORL02
UNICANCER
Phase 2 Completed
NCT01813136 2019-08-16
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Centre Leon Berard
Phase 2 Completed
NCT01639911 2019-07-22
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
University of Illinois at Chicago
Phase 1 Completed
NCT01716416 2019-04-16
HNSCC
Washington University School of Medicine
Phase 1 Completed
NCT01438554 2018-08-29
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00454142 2015-12-17
Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01413113 2015-11-05
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
University of Washington
Phase 1 Completed
NCT01377298 2011-06-21
Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Taiwan University Hospital
Phase 2 Unknown